drug
as of 2026-07-01RBP-7000
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Indivior Inc.
6 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
6
Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia
NCT02203838Phase 3Completed
PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia
NCT02687984Phase 1Completed
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients
NCT02109562Phase 3Completed
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
NCT01677377Phase 2Completed
Single Ascending Dose Study of RBP-7000
NCT02768649Phase 1Completed
First in Man Study of Safety, Tolerability and PK Profile of RBP-7000
NCT02765555Phase 1Completed
KOLs & investigators
3
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
trial
indication
indication
indication
KOL
Philippa Whitelaw, Sr. Dir of Proj Deliver
personKOL score —
Ashley Huston, PMP
personKOL score —
Global Clinical Developoment Manager
personKOL score —